Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study

Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria (PNH). This study assessed noninferiority of ravulizumab to eculizumab in clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Kulasekararaj, Austin G., Hill, Anita, Rottinghaus, Scott T., Langemeijer, Saskia, Wells, Richard, Gonzalez-Fernandez, F. Ataulfo, Gaya, Anna, Lee, Jong Wook, Gutierrez, Emilio Ojeda, Piatek, Caroline I., Szer, Jeff, Risitano, Antonio, Nakao, Shinji, Bachman, Eric, Shafner, Lori, Damokosh, Andrew I., Ortiz, Stephan, Röth, Alexander, Peffault de Latour, Regis
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6368201/
https://ncbi.nlm.nih.gov/pubmed/30510079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-09-876805
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados